Institute of Biology and Medical Genetics, Institute of Physiology, 1st Faculty of Medicine, Charles University, Albertov 4, 128 00, Prague, Czech Republic.
Department of Surgery, Weiden Clinic, Söllnerstraße 16, 92637, Weiden in der Oberpfalz, Germany.
Sci Rep. 2022 Feb 16;12(1):2570. doi: 10.1038/s41598-022-06498-9.
A large proportion of colorectal carcinomas (CRC) evolve from colorectal adenomas. However, not all individuals with colonic adenomas have a risk of CRC substantially higher than those of the general population. The aim of the study was to determine the differences or similarities of mutation profile among low- and high-grade adenomas and in situ carcinoma with detailed follow up. We have investigated the mutation spectrum of well-known genes involved in CRC (such as APC, BRAF, EGFR, NRAS, KRAS, PIK3CA, POLE, POLD1, SMAD4, PTEN, and TP53) in a large, well-defined series of 96 adenomas and in situ carcinomas using a high-throughput genotyping technique. Besides, the microsatellite instability and APC and MLH1 promoter methylation were studied as well. We observed a high frequency of pathogenic variants in the studied genes. The APC, KRAS and TP53 mutation frequencies were slightly lower in adenoma samples than in in situ carcinoma samples. Further, when we stratified mutation frequency based on the grade, the frequency distribution was as follows: low-grade adenoma-high-grade adenomas-in situ carcinoma: APC gene 42.9-56.0-54.5%; KRAS gene 32.7-32.0-45.5%; TP53 gene 8.2-20.0-18.2%. The occurrence of KRAS mutation was associated with the presence of villous histology and methylation of the APC promoter was significantly associated with the presence of POLE genetic variations. However, no association was noticed with the presence of any singular mutation and occurrence of subsequent adenoma or CRC. Our data supports the multistep model of gradual accumulation of mutations, especially in the driver genes, such as APC, TP53 and KRAS.
很大一部分结直肠癌(CRC)是从结直肠腺瘤演变而来的。然而,并非所有患有结肠腺瘤的个体都有比普通人群更高的 CRC 风险。本研究旨在确定低级别和高级别腺瘤以及原位癌之间突变谱的差异或相似性,并进行详细随访。我们使用高通量基因分型技术,在一个由 96 个腺瘤和原位癌组成的大型、明确定义的系列中,研究了参与 CRC 的知名基因(如 APC、BRAF、EGFR、NRAS、KRAS、PIK3CA、POLE、POLD1、SMAD4、PTEN 和 TP53)的突变谱。此外,还研究了微卫星不稳定性以及 APC 和 MLH1 启动子甲基化。我们观察到研究基因中存在高频率的致病性变异。APC、KRAS 和 TP53 突变频率在腺瘤样本中略低于原位癌样本。此外,当我们根据分级对突变频率进行分层时,频率分布如下:低级别腺瘤-高级别腺瘤-原位癌:APC 基因 42.9-56.0-54.5%;KRAS 基因 32.7-32.0-45.5%;TP53 基因 8.2-20.0-18.2%。KRAS 突变的发生与绒毛状组织学有关,APC 启动子的甲基化与 POLE 基因突变的存在显著相关。然而,没有发现任何单一突变的存在与随后的腺瘤或 CRC 的发生有关。我们的数据支持逐渐积累突变的多步骤模型,特别是在 APC、TP53 和 KRAS 等驱动基因中。